Effects of Ang II receptor blocker Irbesartan on adipose tissue function in mice with metabolic disorders (MS: 8577u.R2)

International Journal of Medical Sciences

Volumn 11, Issue 6, 2014, Pages 646-651

  Maeda, Akinobu ^a   Tamura, Kouichi ^a   Wakui, Hiromichi ^a   Ohsawa, Masato ^a   Azushima, Kengo ^a   Uneda, Kazushi ^a   Kobayashi, Ryu ^a   Tsurumi Ikeya, Yuko ^a   Kanaoka, Tomohiko ^a   Dejima, Toru ^a   Ohki, Koji ^a   Haku, Sona ^a   Yamashita, Akio ^a   Umemura, Satoshi ^a  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Adipose tissue; Inflammation; Metabolic disorders; Receptor; Renin angiotensin system

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ASSOCIATED PROTEIN; INTERLEUKIN 6; IRBESARTAN; LEPTIN; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; REGULATOR PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; AGTRAP PROTEIN, MOUSE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BIPHENYL DERIVATIVE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TETRAZOLE DERIVATIVE;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; FOOD INTAKE; GENE EXPRESSION; GLUCOSE METABOLISM; INTERLEUKIN 6 GENE; LEPTIN GENE; LIPID METABOLISM; MALE; METABOLIC DISORDER; MONOCYTE CHEMOTACTIC PROTEIN 1 GENE; MOUSE; NONHUMAN; OBESITY; OXIDATIVE STRESS; PLASMINOGEN ACTIVATOR INHIBITOR 1 GENE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE; TUMOR NECROSIS FACTOR ALPHA GENE; WEIGHT REDUCTION; ANIMAL; BIOSYNTHESIS; BLOOD PRESSURE; BODY WEIGHT; DRUG EFFECTS; GENETICS; HUMAN; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADIPOSE TISSUE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BIPHENYL COMPOUNDS; BLOOD PRESSURE; BODY WEIGHT; HUMANS; LEPTIN; MICE; OBESITY; RECEPTOR, ANGIOTENSIN, TYPE 1; SIGNAL TRANSDUCTION; TETRAZOLES;

EID: 84899648871     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.8577     Document Type: Article

References (39)

1. Maury E, Brichard S M. Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol. 2010; 314: 1-16.
2. Hajer G R, van Haeften T W, Visseren F L. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J. 2008; 29: 2959-71.
3. Jing F, Mogi M, Horiuchi M. Role of renin-angiotensin-aldosterone system in adipose tissue dysfunction. Mol Cell Endocrinol. 2012.
4. Suto J, Matsuura S, Imamura K, et al. Genetic analysis of non-insulin-dependent diabetes mellitus in KK and KK-Ay mice. Eur J Endocrinol. 1998; 139: 654-61.
5. Dol F, Martin G, Staels B, et al. Angiotensin AT1 receptor antagonist irbesartan decreases lesion size, chemokine expression, and macrophage accumulation in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol. 2001; 38: 395-405.
6. Liu B C, Xia H L, Wu J N, et al. Influence of irbesartan on expression of ILK and its relationship with epithelial-mesenchymal transition in mice with unilateral ureteral obstruction. Acta Pharmacol Sin. 2007; 28: 1810-8.
7. Iwai M, Kanno H, Senba I, et al. Irbesartan increased PPARgamma activity in vivo in white adipose tissue of atherosclerotic mice and improved adipose tissue dysfunction. Biochem Biophys Res Commun. 2011; 406: 123-6.
8. Iwamoto T, Kita S, Zhang J, et al. Salt-sensitive hypertension is triggered by Ca2+ entry via Na+/Ca2+ exchanger type-1 in vascular smooth muscle. Nat Med. 2004; 10: 1193-9.
9. Tsurumi Y, Tamura K, Tanaka Y, et al. Interacting molecule of AT1 receptor, ATRAP, is colocalized with AT1 receptor in the mouse renal tubules. Kidney Int. 2006; 69: 488-94.
10. Wakui H, Tamura K, Matsuda M, et al. Intrarenal suppression of angiotensin II type 1 receptor binding molecule in angiotensin II-infused mice. Am J Physiol Renal Physiol. 2010; 299: F991-F1003.
11. Matsuda M, Tamura K, Wakui H, et al. Upstream stimulatory factors 1 and 2 mediate the transcription of angiotensin II binding and inhibitory protein. J Biol Chem. 2013; 288: 19238-49.
12. Wakui H, Tamura K, Tanaka Y, et al. Cardiac-specific activation of angiotensin II type 1 receptor-associated protein completely suppresses cardiac hypertrophy in chronic angiotensin II-infused mice. Hypertension. 2010; 55: 1157-64.
13. Wakui H, Tamura K, Masuda S I, et al. Enhanced angiotensin receptor-associated protein in renal tubule suppresses angiotensin-dependent hypertension. Hypertension. 2013; 61: 1203-10.
14. Wakui H, Dejima T, Tamura K, et al. Activation of angiotensin II type 1 receptor-associated protein exerts an inhibitory effect on vascular hypertrophy and oxidative stress in angiotensin II-mediated hypertension. Cardiovasc Res. 2013; 100: 511-9.
15. Apovian C M, Bigornia S, Mott M, et al. Adipose macrophage infiltration is associated with insulin resistance and vascular endothelial dysfunction in obese subjects. Arterioscler Thromb Vasc Biol. 2008; 28: 1654-9.
16. Neels J G, Olefsky J M. Inflamed fat: what starts the fire? J Clin Invest 2006;116: 33-5.
17. Schenk S, Saberi M, Olefsky J M. Insulin sensitivity: modulation by nutrients and inflammation. J Clin Invest 2008; 118: 2992-3002.
18. Tabata M, Kadomatsu T, Fukuhara S, et al. Angiopoietin-like protein 2 promotes chronic adipose tissue inflammation and obesity-related systemic insulin resistance. Cell Metab. 2009; 10: 178-88.
19. Lazar M A. The humoral side of insulin resistance. Nat Med. 2006; 12: 43-4.
20. Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001; 7: 941-6.
21. Mattu H S, Randeva H S. Role of adipokines in cardiovascular disease. J Endocrinol. 2013; 216: T17-36.
22. Clasen R, Schupp M, Foryst-Ludwig A, et al. PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension. 2005; 46: 137-43.
23. Fujino M, Miura S, Kiya Y, et al. A small difference in the molecular structure of angiotensin II receptor blockers induces AT(1) receptor-dependent and -independent beneficial effects. Hypertens Res. 2010; 33: 1044-52.
24. Banga A, Unal R, Tripathi P, et al. Adiponectin translation is increased by the PPARgamma agonists pioglitazone and omega-3 fatty acids. Am J Physiol Endocrinol Metab. 2009; 296: E480-9.
25. Liu M, Liu F. Transcriptional and post-translational regulation of adiponectin. Biochem J. 2010; 425: 41-52.
26. Matarese G, Mantzoros C, La Cava A. Leptin and adipocytokines: bridging the gap between immunity and atherosclerosis. Curr Pharm Des. 2007; 13: 3676-80.
27. Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994; 372: 425-32.
28. Lago F, Dieguez C, Gomez-Reino J, et al. Adipokines as emerging mediators of immune response and inflammation. Nat Clin Pract Rheumatol. 2007; 3: 716-24.
29. Bouloumie A, Marumo T, Lafontan M, et al. Leptin induces oxidative stress in human endothelial cells. FASEB J. 1999; 13: 1231-8.
30. Beltowski J. Leptin and atherosclerosis. Atherosclerosis. 2006; 189: 47-60.
31. Matsushita K, Takeuchi O, Standley D M, et al. Zc3h12a is an RNase essential for controlling immune responses by regulating mRNA decay. Nature. 2009; 458: 1185-90.
32. Azuma K, Tamura K, Shigenaga A, et al. Novel regulatory effect of angiotensin II type 1 receptor-interacting molecule on vascular smooth muscle cells. Hypertension. 2007; 50: 926-32.
33. Tanaka Y, Tamura K, Koide Y, et al. The novel angiotensin II type 1 receptor (AT1R)-associated protein ATRAP downregulates AT1R and ameliorates cardiomyocyte hypertrophy. FEBS Lett. 2005; 579: 1579-86.
34. Horiuchi M, Iwanami J, Mogi M. Regulation of angiotensin II receptors beyond the classical pathway. Clin Sci. 2012; 123: 193-203.
35. Mogi M, Iwai M, Horiuchi M. Emerging concepts of regulation of angiotensin II receptors: new players and targets for traditional receptors. Arterioscler Thromb Vasc Biol. 2007; 27: 2532-9.
36. Tamura K, Tanaka Y, Tsurumi Y, et al. The role of angiotensin AT1 receptor-associated protein in renin-angiotensin system regulation and function. Curr Hypertens Rep. 2007; 9: 121-7.
37. Tamura K, Wakui H, Maeda A, et al. The physiology and pathophysiology of a novel angiotensin receptor-binding protein ATRAP/Agtrap. Curr Pharm Des. 2013; 19: 3043-48.
38. Shigenaga A, Tamura K, Wakui H, et al. Effect of olmesartan on tissue expression balance between angiotensin II receptor and its inhibitory binding molecule. Hypertension. 2008; 52: 672-8.
39. Dejima T, Tamura K, Wakui H, et al. Prepubertal angiotensin blockade exerts long-term therapeutic effect through sustained ATRAP activation in salt-sensitive hypertensive rats. J Hypertens. 2011; 29: 1919-29.